1. McGoon MD, Miller DP. Reveal: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev 2012;21:8–18.
2. Humbert M, Sitbon O, Yaïci A, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010;36:549–555.
3. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296–301.
4. Tapson VF, Torres F, Kermeen F. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012;142:1383–1390.
5. National Institutes of Health. Study in subjects with PAH and PH secondary to IPF using inhaled NITROsyl (PHiano) [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Jan 14, 2013]. Available from:
http://clinicaltrialsgov/ct2/show/NCT01265888
6. Rubin L, Pulido T, Channick R, et al. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): results from the SERAPHIN Trial. CHEST 2012;142(4_MeetingAbstracts):1026A.
7. National Institutes of Health. Long-term extension study of the SERAPHIN Study, to assess the safety and tolerability of ACT 064992 in patients with symptomatic pulmonary arterial hypertension (SERAPHIN OL) [Internet]. Bethesda (MD): National Institutes of Health, c2008 [cited last updated Oct 23, 2012]. Available from:
http://clinicaltrials.gov/ct2/show/NCT00667823
8. Simonneau G, Lang I, Torbicki A, et al. Efficacy, safety and tolerability of ACT-293987, a novel oral, non-prostanoid, prostaglandin I2 (IP) receptor agonist: results from a phase IIa study in pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2010;181:A2515.
10. Rubin L, Parikh K, Pulido T, et al. FREEDOM-M: efficacy and safety of oral treprostinil diethanolamine as monotherapy in patients with pulmonary arterial hypertension. CHEST 2011;140(4_MeetingAbstracts):1044A.
11. Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013;127:624–633.
12. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792–799.
13. Ghofrani H, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study (PATENT-1). CHEST 2012;142(4_MeetingAbstracts):1027A.
14. National Institutes of Health. BAY63-2521: long-term extension study in patients with pulmonary arterial hypertension (PATENT-2) [Internet]. Bethesda (MD): National Institutes of Health, c2009 [cited last updated Jan 9, 2013]. Available from:
http://clinicaltrials.gov/ct2/show/NCT00863681
15. National Institutes of Health. Evaluation of the pharmacodynamic effect of the combination of sildenafil and riociguat on blood pressure and other safety parameters (PATENT PLUS) [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Nov 28, 2012]. Available from:
http://clinicaltrials.gov/ct2/show/NCT01179334
16. National Institutes of Health. A phase 2, multi-center, openlabel study to evaluate the intermediate/long-term safety and efficacy of air001 on subjects with WHO group 1 pulmonary arterial hypertension [Internet]. Bethesda (MD): National Institutes of Health, c2012 [cited last updated Nov 29, 2012]. Available from:
http://clinicaltrials.gov/ct2/show/NCT01725269
17. Waxman AB, Lawler L, Cornett G. Cicletanine for the treatment of pulmonary arterial hypertension. Arch Intern Med 2008;168:2164–2166.
18. Gomberg-Maitland M, Oudiz R, Shapiro S, et al. Cicletanine as add-on therapy for pulmonary arterial hypertension. CHEST 2012;142(4_MeetingAbstracts):806A.
20. National Institutes of Health. Imatinib (QTI571) in pulmonary arterial hypertension (IMPRES) [Internet]. Bethesda (MD): National Institutes of Health, c2009 [cited last updated Aug 13, 2012]. Available from:
ttp://clinicaltrials.gov/ct2/show/record/NCT00902174
21. National Institutes of Health. Extension to QTI571A2301 to evaluate the long-term safety, tolerability and efficacy of imatinib in severe pulmonary arterial hypertension (IMPRES Extn) [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Jan 2, 2013]. Available from:
http://clinicaltrials.gov/ ct2/show/NCT01117987
22. National Institutes of Health. Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension (PAH) [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Oct 1, 2012]. Available from:
http://clinicaltrials.gov/ct2/show/NCT01179737
23. National Institutes of Health. Rituximab for treatment of systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Nov 28, 2012]. Available from:
http://clinicaltrials.gov/ ct2/show/NCT01086540
25. Mouchaers KT, Schalij I, de Boer MA, et al. Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil. Eur Respir J 2010;36:800–807.
26. Fukumoto Y, Shimokawa H. Recent progress in the management of pulmonary hypertension. Circ J 2011;75:1801–1810.
27. Ishikura K, Yamada N, Ito M, et al. Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006;70:174–178.
28. Fujita H, Fukumoto Y, Saji K, et al. Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension. Heart Vessels 2010;25:144–149.
30. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129–1135.
31. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 2005;127:1446–1452.
33. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249–254.
34. O'Callaghan DS, Savale L, Montani D, et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011;8:526–538.
36. Galie N, Boonstra A, Ewert R, et al. Effects of inhaled aviptadil (vasoactive intestinal peptide) in patients with pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2010;181:A2516.
37. Wang XX, Zhang FR, Shang YP, et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 2007;49:1566–1571.
38. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006;28:691–694.
39. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:1257–1263.
40. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915–1922.
41. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521–530.
42. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894–2903.
43. Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011;30:632–643.
44. Benza RL, Gupta H, Soto FJ, et al. Safety and efficacy of bosentan in combination with sildenafil in PAH patients who experience inadequate clinical response to monotherapy: the COMPASS-3 Study. CHEST 2010;138(4_MeetingAbstracts):840A.
45. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353–359.
46. Kemp K, Savale L, O'Callaghan DS, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant 2012;31:150–158.
47. National Institutes of Health. A study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH) (AMBITION) [Internet]. Bethesda(MD): National Institutes of Health, c2010 [cited last updated Feb 13, 2013]. Available from:
http://clinicaltrials.gov/ct2/show/study/NCT01178073
48. National Institutes of Health. A 48-week study of the effect of dual therapy (inhaled treprostinil and tadafafil) versus monotherapy (tadalafil), 2 FDA approved pulmonary hypertension medications [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Feb 24, 2011]. Available from:
http://clinicaltrials. gov/ct2/show/study/NCT01305252
50. National Institutes of Health. Dichloroacetate (DCA) for the treatment of pulmonary arterial hypertension [Internet]. Bethesda (MD): National Institutes of Health, c2010 [cited last updated Nov 3, 2011]. Available from:
http://clinicaltrials.gov/ct2/show/NCT01083524
51. Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009;4:853–865.
52. National Institutes of Health. Pulmonary hypertension: assessment of cell therapy (PHACeT) [Internet]. Bethesda (MD): National Institutes of Health, c2007 [cited last updated Jun 6, 2011]. Available from:
http://clinicaltrials.gov/ct2/show/NCT00469027
53. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. Cardiovasc Ther 2011;30:93–99.
54. Oudiz R, Shapiro S, Torres F, et al. ATHENA-1: hemodynamic improvements following the addition of ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension. Chest 2011;140(4_MeetingAbstracts):905A.
55. National Institutes of Health. Study providing monotherapy (sitaxsentan) and combination therapy (sitaxsentan+sildenafil) to subjects with pulmonary arterial hypertension (PAH) to assess long-term safety [Internet]. Bethesda (MD): National Institutes of Health, c2008 [cited last updated Jan 20, 2012]. Available from:
http://clinicaltrials.gov/show/NCT00796510